Market Overview

Oppenheimer Reviews BioCryst Earnings

Share:
Related BCRX
Mid-Morning Market Update: Markets Edge Lower; Sotheby's Beats Q4 Views
22 Stocks Moving In Monday's Pre-Market Session
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q4 2016 Results - Earnings Call Transcript (Seeking Alpha)
Related DYAX
Here Are The Most Notable Insider Transactions Hitting The Market
Stocks Hitting 52-Week Highs

In a report published Monday, Oppenheimer analysts maintained a Perform rating on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), saying that clinical data could drive the stock higher in 2H15.

BioCryst reported its 1Q15 revenue and EPS at $6.8M and ($0.21), as compared to the Oppenheimer estimates of $3.2M and ($0.26), respectively.

In the report Oppenheimer noted the upcoming milestones for BioCryst as:

  • Phase 1a PK/PD/safety data from BCX7353 in 3Q15
  • Phase 2b data from BCX4161 (OPuS-2 trial) in 4Q15
  • Initiation of a Phase 1b proof-of-concept trial of BCX7353 in 4Q15

"We reiterate our Perform rating on BCRX fundamentals, but see opportunity for share price appreciation in 2H15," the analysts said, citing the "large valuation gap" to competitor Dyax Corp. (NASDAQ: DYAX) and "in anticipation of BCX7353 and BCX4161 readouts in 3Q and 4Q15, respectively."

Latest Ratings for BCRX

DateFirmActionFromTo
Feb 2017Ladenburg ThalmannInitiates Coverage OnBuy
Dec 2016JMP SecuritiesUpgradesMarket PerformMarket Outperform
Aug 2016PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BCRX + DYAX)

View Comments and Join the Discussion!